Published in J Clin Oncol on February 01, 1994
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol (2010) 1.12
Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer (2011) 0.95
Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J (2010) 0.92
The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. Can Urol Assoc J (2016) 0.80
Barriers and facilitators for clinical trial participation among diverse Asian patients with breast cancer: a qualitative study. BMC Womens Health (2016) 0.80
Characteristics of advanced cancer patients with cancer-related fatigue enrolled in clinical trials and patients referred to outpatient palliative care clinics. J Pain Symptom Manage (2012) 0.79
The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer. Am J Clin Oncol (2016) 0.78
The influence of conservative surgical practices for malignant ovarian germ cell tumors. J Surg Oncol (2008) 0.78
Identification of underserved areas for urologic cancer care. Cancer (2014) 0.78
Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience. Br J Cancer (1996) 0.77
Application of the International Germ Cell Consensus Classification to the Nova Scotia population of patients with germ cell tumours. Can Urol Assoc J (2009) 0.75
Hospital surgical volume, utilization, costs and outcomes of retroperitoneal lymph node dissection for testis cancer. Adv Urol (2012) 0.75
Semiparametric Bayesian approaches to joinpoint regression for population-based cancer survival data. Comput Stat Data Anal (2009) 0.75
Clinical trial information as a measure of quality cancer care. J Oncol Pract (2010) 0.75
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials (2000) 6.17
The analysis of multiple endpoints in clinical trials. Biometrics (1987) 3.83
The role of increasing detection in the rising incidence of prostate cancer. JAMA (1995) 3.79
The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat Med (1999) 3.53
Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2007) 3.24
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst (1994) 2.92
Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst (1996) 2.91
Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. Control Clin Trials (2000) 2.67
Trends in biomarker research for cancer detection. Lancet Oncol (2001) 2.46
Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol (1998) 2.44
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
Isochromosome of the short arm of chromosome 12: clinically useful markers for male germ cell tumors. J Natl Cancer Inst (1989) 2.19
National cancer clinical trials: children have equal access; adolescents do not. J Adolesc Health (1997) 2.17
Ischemia during ambulatory monitoring as a prognostic indicator in patients with stable coronary artery disease. JAMA (1997) 2.17
On the design and analysis of randomized clinical trials with multiple endpoints. Biometrics (1993) 2.13
Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst (1996) 2.12
Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology (2000) 2.10
Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation (2000) 2.07
Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet (1981) 2.06
Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993--the perspective of NIH clinical trialists. Control Clin Trials (1995) 2.04
Prostate cancer incidence and mortality rates among white and black men. Epidemiology (1997) 1.95
Breast cancer trends of black women compared with white women. Arch Fam Med (1999) 1.91
Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care (1998) 1.88
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol (1996) 1.85
Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia. Am J Med (1982) 1.84
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol (2000) 1.82
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol (1994) 1.78
A medicolegal curriculum for internal medicine residents. J Gen Intern Med (1999) 1.78
Study design in the evaluation of breast cancer imaging technologies. Acad Radiol (2000) 1.71
Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol (1994) 1.69
Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med (1987) 1.68
Teratoma with malignant transformation in germ cell tumors in men. Cancer (1985) 1.66
Americans' knowledge of cancer risk and survival. Prev Med (1997) 1.63
Neurons in monkey prefrontal cortex that track past or predict future performance. Science (2000) 1.62
How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach. Am J Epidemiol (1992) 1.59
Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. J Natl Cancer Inst (1991) 1.55
Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke (1996) 1.55
Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer (2001) 1.52
Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol (2000) 1.51
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol (1992) 1.50
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol (1996) 1.49
High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J Natl Cancer Inst (1992) 1.49
Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med (1981) 1.47
Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation (2001) 1.46
Mediastinal growing teratoma syndrome. Ann Thorac Surg (1997) 1.44
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol (1995) 1.44
Race and outcomes: is this the end of the beginning for minority health research? J Natl Cancer Inst (1999) 1.43
Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study. J Am Coll Cardiol (1994) 1.43
Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst (1991) 1.42
Good for women, good for men, bad for people: Simpson's paradox and the importance of sex-specific analysis in observational studies. J Womens Health Gend Based Med (2001) 1.41
Continued refinement in the treatment of germ cell tumour patients. Eur J Cancer (1991) 1.40
Bleomycin in germ cell tumor therapy: not all regimens are created equal. J Clin Oncol (1997) 1.39
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol (1990) 1.38
Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res (1983) 1.38
Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer (1991) 1.36
The Asymptomatic Cardiac Ischemia Pilot (ACIP) study: design of a randomized clinical trial, baseline data and implications for a long-term outcome trial. J Am Coll Cardiol (1994) 1.34
Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res (1987) 1.34
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol (1997) 1.34
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol (1994) 1.33
Carcinoma of major salivary glands. Recent trends. Arch Otolaryngol Head Neck Surg (1989) 1.32
Biochemical characterization of the amphotropic group of murine leukemia viruses. J Virol (1978) 1.31
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol (1985) 1.31
Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics (1987) 1.30
Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol (1999) 1.28
Closed testing procedures for group sequential clinical trials with multiple endpoints. Biometrics (1999) 1.28
Hemorrhage: a complication of metastatic testicular choriocarcinoma. Urology (1987) 1.28
Monitoring pairwise comparisons in multi-armed clinical trials. Biometrics (1994) 1.25
The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control (1998) 1.25
Asymptomatic Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP Investigators. J Am Coll Cardiol (1995) 1.22
Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol (1988) 1.21
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol (2000) 1.21
Surgery for a post-chemotherapy residual mass in seminoma. J Urol (1997) 1.20
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol (1994) 1.20
The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: the Memorial Sloan-Kettering Cancer Center experience (1975 to 1982). J Clin Oncol (1985) 1.19
Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial. J Pediatr (1983) 1.17
Induced abortion, bias, and breast cancer: why epidemiology hasn't reached its limit. J Natl Cancer Inst (1996) 1.16
A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis (1994) 1.15
Analysis of autopsy evaluations of ovarian cancer patients treated at the National Cancer Institute, 1972-1988. Am J Clin Oncol (2000) 1.14
The paired availability design for historical controls. BMC Med Res Methodol (2001) 1.13
Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res (1990) 1.12
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol (2001) 1.11
Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators. J Am Coll Cardiol (2000) 1.11
Efficacy of injectable and oral paste formulations of ivermectin against gastrointestinal parasites in ponies. Am J Vet Res (1982) 1.09
Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. Cell Growth Differ (1997) 1.08
Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials (1995) 1.08
A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol (1988) 1.08
Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head Neck (1997) 1.08
Differences in reported food frequency by season of questionnaire administration: the 1987 National Health Interview Survey. Epidemiology (1994) 1.07
Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol (1993) 1.07
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol (1994) 1.07
A method for assessing house staff workload as a function of length of stay. JAMA (2001) 1.06
Equal participation of minority patients in U.S. national pediatric cancer clinical trials. J Pediatr Hematol Oncol (1997) 1.06
Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res (1992) 1.05
The impact of breakthrough clinical trials on survival in population based tumor registries. J Clin Epidemiol (1991) 1.05